FCPA In The China Framework Warrants Special Attention
This article was originally published in PharmAsia News
Executive Summary
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
You may also be interested in...
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors
Astellas Pharma is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.